Track the CG Oncology, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €6.6bn. The latest transaction was reported on 31 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: POST LEONARD E. Every trade is accessible without an account.
75
Insider Decl.
n/a
Thresholds
€50m
5 ops.
Buy Volume
€37m
15 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CG Oncology, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$91.08.
39Σ signal
Buys €50m€37m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 27,203 of 29,053 companies
17.6
score / 100
Value
28
Quality
7
FCF yld-2.0%
Earn yld-2.4%
EV/EBITDA·
ROE-26%
Gross mgn-15%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
24,165 shares@ US$75.160.028% mcap33.6% of flowCommon StockSEC:0001193125-26-303188:1
25 of 75 declarations
About CG Oncology, Inc.
CG Oncology, Inc. is a company focused on developing innovative treatments for cancer. It specializes in targeted therapies and immunological approaches to improve patient outcomes.